{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:27:30Z","timestamp":1788532050959,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:p>\n                    Mucosal healing represents a critical therapeutic endpoint in inflammatory bowel disease (IBD), yet reliable noninvasive predictive biomarkers remain limited. Serum gelsolin (GSN) has emerged as a potential inflammatory biomarker, but its dynamic changes and predictive value for mucosal healing have not been systematically investigated. This study aimed to develop and internally validate a predictive model integrating dynamic GSN changes with clinical parameters for forecasting 6-month mucosal healing in IBD patients. We enrolled 298 IBD patients (182 Crohn disease, 116 ulcerative colitis) from a tertiary referral center and collected baseline and 6-month follow-up data including serum GSN levels, endoscopic scores, and clinical parameters. The primary endpoint was mucosal healing at 6 months (Mayo endoscopic score\u2005\u22641 or SES-CD\u2005&lt;3). Linear mixed-effects models analyzed GSN longitudinal trajectories, identifying 3 change patterns through growth mixture modeling. Least absolute shrinkage and selection operator regression selected variables from 12 candidates, and random forest algorithms constructed prediction models. Time-dependent receiver operating characteristic curves evaluated predictive performance. Internal validation was performed using bootstrap resampling (1000 iterations). Propensity score matching compared GSN patterns between biologic responders and nonresponders. Restricted cubic splines examined GSN\u2013mucosal healing relationships. Three distinct GSN change patterns emerged: rapid-increase (38.6%), slow-increase (42.3%), and nonresponse (19.1%). The integrated prediction model incorporating baseline GSN, \u0394GSN, CRP\/GSN ratio, and endoscopic scores demonstrated superior predictive performance (AUC 0.873, 95% CI 0.841 to 0.905) compared to models using clinical parameters alone (AUC 0.742,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). Bootstrap internal validation confirmed model stability (optimism-corrected AUC 0.869\u2005\u00b1\u20050.018). decision curve analysis (DCA) revealed clinical net benefit across threshold probabilities of 10% to 60%. Among biologic-treated patients, rapid-increase GSN pattern was associated with higher mucosal healing rates (HR 3.24, 95% CI 2.15\u20134.89,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). Dynamic GSN monitoring combined with clinical parameters shows promising predictive performance for mucosal healing in IBD under internal validation. This integrated approach may enable early identification of treatment responders and inform therapeutic decision-making, though external validation and cost-effectiveness analyses are needed before clinical implementation.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048832","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:01:43Z","timestamp":1778896903000},"page":"e48832","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic changes in serum gelsolin combined with clinical parameters to construct a predictive model for mucosal healing in inflammatory bowel disease: A prospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7071-7324","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Miao","sequence":"additional","affiliation":[{"name":"Unit 94831, People\u2019s Liberation Army of China, Nanping, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anquan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease.","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages.","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41575-025-01063-x","article-title":"Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.","volume":"22","author":"Solitano","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn\u2019s disease.","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"1479666","DOI":"10.3389\/fphar.2025.1479666","article-title":"Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores.","volume":"16","author":"Shim","year":"2025","journal-title":"Front Pharmacol"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"3467419","DOI":"10.1155\/2020\/3467419","article-title":"The relationship between C-reactive protein\/albumin ratio and disease activity in patients with inflammatory bowel disease.","volume":"2020","author":"Chen","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41598-020-57508-7","article-title":"Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn\u2019s disease in Japan.","volume":"10","author":"Shiga","year":"2020","journal-title":"Sci Rep"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"17562848251362570","DOI":"10.1177\/17562848251362570","article-title":"Performance of serum gelsolin as a biomarker for mucosal activity in Crohn\u2019s disease: a comparison with C-reactive protein.","volume":"18","author":"Maeda","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines10040872","article-title":"Gelsolin as a potential biomarker for endoscopic activity and mucosal healing in ulcerative colitis.","volume":"10","author":"Maeda","year":"2022","journal-title":"Biomedicines"},{"key":"R12-20260904","first-page":"e59009","article-title":"C-reactive protein: an inflammatory biomarker and a predictor of neurodegenerative disease in patients with inflammatory bowel disease?","volume":"16","author":"Muresan","year":"2024","journal-title":"Cureus"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"12431","DOI":"10.1038\/s41598-021-90558-z","article-title":"C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.","volume":"11","author":"Ishida","year":"2021","journal-title":"Sci Rep"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1007\/s10753-025-02303-7","article-title":"From homeostasis to inflammation to autoimmunity: the potential impact of CRP.","volume":"48","author":"Ahmed","year":"2025","journal-title":"Inflammation"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ecco-jcc\/jjab155","article-title":"Machine learning-based prediction models for diagnosis and prognosis in inflammatory bowel diseases: a systematic review.","volume":"16","author":"Nguyen","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"1637159","DOI":"10.3389\/fimmu.2025.1637159","article-title":"Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel disease.","volume":"16","author":"De Deo","year":"2025","journal-title":"Front Immunol"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/cancers17142337","article-title":"Artificial intelligence in advancing inflammatory bowel disease management: setting new standards.","volume":"17","author":"Labarile","year":"2025","journal-title":"Cancers"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD statement.","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/ibd\/izab187","article-title":"Machine learning predictive outcomes modeling in inflammatory bowel diseases.","volume":"28","author":"Javaid","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/jcm14051536","article-title":"Paradigm shift in inflammatory bowel disease management: precision medicine, artificial intelligence, and emerging therapies.","volume":"14","author":"Caballero Mateos","year":"2025","journal-title":"J Clin Med"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cgh.2024.04.042","article-title":"The IBD clinic of tomorrow: holistic, patient-centric, and value-based care.","volume":"23","author":"Click","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2020.00123","article-title":"Serum biomarkers for inflammatory bowel disease.","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.3390\/jcm10204745","article-title":"Machine learning prediction model for inflammatory bowel disease based on laboratory markers. Working model in a discovery cohort study.","volume":"10","author":"Kraszewski","year":"2021","journal-title":"J Clin Med"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12874-025-02481-w","article-title":"Propensity score matching: should we use it in designing observational studies?","volume":"25","author":"Wan","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12911-023-02407-w","article-title":"Comparison of LASSO and random forest models for predicting the risk of premature coronary artery disease.","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","article-title":"A simple, step-by-step guide to interpreting decision curve analysis.","volume":"3","author":"Vickers","year":"2019","journal-title":"Diagn Progn Res"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"2101186","DOI":"10.1183\/13993003.01186-2021","article-title":"Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models.","volume":"58","author":"Sadatsafavi","year":"2021","journal-title":"Eur Respir J"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/postmj\/qgae027","article-title":"Understanding decision curve analysis in clinical prediction model research.","volume":"100","author":"Zhao","year":"2024","journal-title":"Postgrad Med J"},{"key":"R29-20260904","doi-asserted-by":"crossref","first-page":"107745","DOI":"10.3748\/wjg.v31.i29.107745","article-title":"Positioning and sequencing of advanced therapies in inflammatory bowel disease: a guide for clinical practice.","volume":"31","author":"Imbrizi","year":"2025","journal-title":"World J Gastroenterol"},{"key":"R30-20260904","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12874-021-01452-1","article-title":"Evaluating the performance of propensity score matching-based approaches in individual patient data meta-analysis.","volume":"21","author":"Johara","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"R31-20260904","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease.","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R32-20260904","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ibd\/izaa073","article-title":"A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to anti-TNF therapy.","volume":"27","author":"Yao","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R33-20260904","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2021.12.245","article-title":"How do we predict a patient\u2019s disease course and whether they will respond to specific treatments?","volume":"162","author":"Verstockt","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:02:26Z","timestamp":1788530546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":33,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048832","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2026-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}